Log in to MyACC
The Clinical Spotlight Series shines a light on best practices and emerging science across practice-changing topics in care including atrial fibrillation, SGLT2is, heart failure, lipid management, and anticoagulation.
Join leading experts in the field for this series of interactive sessions to ensure you are up to date on the safety and efficacy of the newest therapies, and cultivate your skills in applying the latest clinical information into patient care.
Optimize statin therapy and the real-world selection, sequencing, and escalation of non-statin therapies to ensure optimal management of dyslipidemia to improve patient outcomes.
Chair: Martha Gulati, MD, MS, FACC
Learn about AF management including early rhythm control, challenges with DOACs, non-pharmacological alternatives to anticoagulation, and guidance for triple therapy.
Chair: Julia H. Indik, MD, PhD, FACC
Gain insights on the practical components of SGLT2is including patient selection, initiation, dosing, sequencing, and monitoring to successfully incorporate these agents into practice.
Chair: Alison L. Bailey, MD, FACC
Test your knowledge and compete against your peers at this cross-cutting interactive session covering anticoagulation for AFib, PAD, VTE, and COVID.
Chair: Geoff Barnes, MD, MSc, FACC
Understand the nuanced considerations for patient selection and get the latest strategies on appropriately using new nonstatin agents in clinical practice.
Chair: Salim Virani, MD, FACC
Gain insights from new trial results for SGLT2is on the latest science and practical applications you need to deliver cutting-edge therapy to your patients.
Chair: Alison Bailey, MD, FACC
Navigate the new and complex heart failure management landscape, including understanding emerging therapies and their practical applications.
Chair: Alanna Morris, MD, MSc, FACC
This series is supported by independent educational grants from Amgen, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company, Bristol-Myers Squibb and Pfizer Alliance, Cytokinetics, Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, Merck Sharp & Dohme Corp., Novartis, and Sanofi.
